Aurinia Pharmaceuticals Inc
AUPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.12B
Close$
$7.01
62.4% downside
Current Fair Value
62.4% downsideOvervalued by 62.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.12 Billion |
|---|---|
| Enterprise Value | $2.15 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.14 |
| Beta | 1.43 |
| Outstanding Shares | 132,375,000 |
Return
| Return on Equity | 52.54% |
|---|---|
| Return on Assets | 41.19% |
| Return on Invested Capital | 20.94% |
Valuation & Multiples
| P/E Ratio | 7.35 |
|---|---|
| PEG | 15.58 |
| Price to Sales | 9.31 |
| Price to Book Ratio | 4.66 |
| Enterprise Value to Revenue | 7.21 |
| Enterprise Value to EBIT | 16.11 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.13 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$0.18
Average shareholder expectationRevenue Estimate
$76.98 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$80.94 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.8032▲ 17.92% |
|---|---|
| Total Calls | 365,800▼ 59.36% |
| Total Puts | 293,800▼ 47.69% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 55.00%▲ 2.25% |
|---|---|
| Total Invested | $1.09B▼ 5.28% |
| Investors Holding | 2740% |
ESG Score
No data
About Aurinia Pharmaceuticals Inc
CEO: Peter Greenleaf